Ezh2 is Required for Developmental Stage-Specific Silencing of Oncofetal Genes in Hematopoietic Stem/Progenitor Cells

Motohiko Oshima,Satoru Miyagi,Shuhei Koide,George Russel Wendt,Nagisa Hasegawa,Shogo Yabata,Changshan Wang,Yutaka Suzuki,Atsushi Iwama
DOI: https://doi.org/10.1182/blood.v124.21.2900.2900
IF: 20.3
2014-01-01
Blood
Abstract:In contrast to adult bone marrow (BM) hematopoiesis, fetal liver (FL) hematopoiesis involves mainly erythropoiesis and myelopoiesis, with limited lymphopoiesis. Fetal hematopoietic stem cells (HSCs) are known to have greater repopulating capacity as compared with adult HSCs. Polycomb group (PcG) protein Ezh2 participates in gene silencing by catalyzing the trimethylation on H3K27 (H3K27me3). We previously reported that in transplantation assays, Ezh2-deficient FL hematopoietic cells have greater reconstitution capacity and establish significantly higher ratios of myeloid to lymphoid reconstitution relative to wild-type (WT). From these results, we hypothesized that adult BM hematopoietic cells repopulated with Ezh2-deficient FL cells partially retain the features of fetal hematopoietic cells as compared with WT.
What problem does this paper attempt to address?